LU91436I2 - "Combinaison comprenant de la vildagliptine ou un de ses sels pharmaceutiquement acceptable et de lametformine ou un de ses sels pharmaceutiquement a cceptable (EUCREAS)" - Google Patents

"Combinaison comprenant de la vildagliptine ou un de ses sels pharmaceutiquement acceptable et de lametformine ou un de ses sels pharmaceutiquement a cceptable (EUCREAS)"

Info

Publication number: LU91436I2
Authority: LU; Luxembourg
Prior art keywords: inhibitors; insulin; pharmaceutically acceptable; acceptable salt; glucose
Prior art date: 2000-01-21

Application number

LU91436C

Other languages

English (en)

Other versions

LU91436I9 (fr

Original Assignee

Novartis Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-21

Filing date

2008-05-09

Publication date

2008-07-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27049636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91436(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-05-09 Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag

2008-07-09 Publication of LU91436I2 publication Critical patent/LU91436I2/fr

2019-01-02 Publication of LU91436I9 publication Critical patent/LU91436I9/fr

Links

SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 title abstract 3
229960001254 vildagliptin Drugs 0.000 title abstract 2
150000003839 salts Chemical class 0.000 title 2
UOXXTZDTECBLDK-FRWZKJFKSA-N 3-(diaminomethylidene)-1,1-dimethylguanidine (2R)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound CN(C)C(=N)N=C(N)N.OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@@H]1C#N UOXXTZDTECBLDK-FRWZKJFKSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 abstract 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 3
208000002705 Glucose Intolerance Diseases 0.000 abstract 2
102000003638 Glucose-6-Phosphatase Human genes 0.000 abstract 2
108010086800 Glucose-6-Phosphatase Proteins 0.000 abstract 2
102000007390 Glycogen Phosphorylase Human genes 0.000 abstract 2
108010046163 Glycogen Phosphorylase Proteins 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 2
102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 abstract 2
101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 abstract 2
239000003623 enhancer Substances 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
201000009104 prediabetes syndrome Diseases 0.000 abstract 2
108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 2
VFFZWMWTUSXDCB-ZDUSSCGKSA-N 6-[2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNCCNC1=CC=C(C#N)C=N1 VFFZWMWTUSXDCB-ZDUSSCGKSA-N 0.000 abstract 1
208000010444 Acidosis Diseases 0.000 abstract 1
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
102000027487 Fructose-Bisphosphatase Human genes 0.000 abstract 1
108010017464 Fructose-Bisphosphatase Proteins 0.000 abstract 1
229940122904 Glucagon receptor antagonist Drugs 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
208000007976 Ketosis Diseases 0.000 abstract 1
206010027417 Metabolic acidosis Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
239000000674 adrenergic antagonist Substances 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
230000030136 gastric emptying Effects 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
230000009229 glucose formation Effects 0.000 abstract 1
230000002440 hepatic effect Effects 0.000 abstract 1
230000001771 impaired effect Effects 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
230000004140 ketosis Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229930029653 phosphoenolpyruvate Natural products 0.000 abstract 1
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000019491 signal transduction Effects 0.000 abstract 1
150000003384 small molecules Chemical class 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

LU91436C 2000-01-21 2008-05-09 "Combinaison comprenant de la vildagliptine ou un de ses sels pharmaceutiquement acceptable et de lametformine ou un de ses sels pharmaceutiquement a cceptable (EUCREAS)" LU91436I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US48923400A	2000-01-21	2000-01-21
US61926200A	2000-07-19	2000-07-19
EP01909661A EP1248604B2 (fr)	2000-01-21	2001-01-19	Combinaisons comprenant un inhibiteur de la dipeptidylpeptidase - iv

Publications (2)

Publication Number	Publication Date
LU91436I2 true LU91436I2 (fr)	2008-07-09
LU91436I9 LU91436I9 (fr)	2019-01-02

Family

ID=27049636

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91436C LU91436I2 (fr)	2000-01-21	2008-05-09	"Combinaison comprenant de la vildagliptine ou un de ses sels pharmaceutiquement acceptable et de lametformine ou un de ses sels pharmaceutiquement a cceptable (EUCREAS)"

Country Status (17)

Country	Link
US (1)	US20030139434A1 (fr)
EP (5)	EP1743655B1 (fr)
JP (7)	JP2003520226A (fr)
CN (3)	CN1977842A (fr)
AT (2)	ATE385421T1 (fr)
AU (1)	AU2001237321A1 (fr)
BR (1)	BRPI0107715B8 (fr)
CA (2)	CA2673615C (fr)
CY (6)	CY1106303T1 (fr)
DE (3)	DE122008000018I1 (fr)
DK (5)	DK1741446T3 (fr)
ES (5)	ES2487897T3 (fr)
FR (1)	FR08C0017I2 (fr)
LU (1)	LU91436I2 (fr)
NL (1)	NL300346I1 (fr)
PT (5)	PT1743655E (fr)
WO (1)	WO2001052825A2 (fr)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2684168B2 (ja)	1995-10-30	1997-12-03	トーワ株式会社	離型抵抗力測定方法及び測定装置
US6284748B1 (en)	1997-03-07	2001-09-04	Metabasis Therapeutics, Inc.	Purine inhibitors of fructose 1,6-bisphosphatase
KR100818845B1 (ko)	1998-09-09	2008-04-01	메타베이시스 테라퓨틱스, 인크.	신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
EP1113804A2 (fr) *	1998-09-17	2001-07-11	Akesis Pharmaceuticals, Inc.	Compositions et traitements contre les troubles du metabolisme du glucose
EP1743655B1 (fr) *	2000-01-21	2014-06-25	Novartis AG	Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
JP2003525944A (ja)	2000-03-08	2003-09-02	メタバシス・セラピューティクス・インコーポレイテッド	新規アリールフルクトース−１，６−ビスホスファターゼ阻害剤
GB0014969D0 (en) *	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
US7078397B2 (en)	2000-06-19	2006-07-18	Smithkline Beecham Corporation	Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US7563774B2 (en)	2000-06-29	2009-07-21	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1372660A2 (fr) *	2000-07-06	2004-01-02	Metabasis Therapeutics, Inc.	Combinaison d'inhibiteurs de fbpase et d'agents antidiabetiques utile pour le traitement du diabete
CN100525768C (zh) *	2000-10-23	2009-08-12	史密丝克莱恩比彻姆公司	新化合物
ATE380175T1 (de)	2001-06-27	2007-12-15	Smithkline Beecham Corp	Pyrrolidine als dipeptidyl peptidase inhibitoren
JP4357293B2 (ja)	2001-06-27	2009-11-04	スミスクラインビーチャムコーポレーション	ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
CN1723196A (zh)	2001-06-27	2006-01-18	史密丝克莱恩比彻姆公司	作为二肽酶抑制剂的氟代吡咯烷
GB0205162D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205175D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205170D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205166D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205176D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205165D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
JP3813152B2 (ja)	2002-03-12	2006-08-23	メルクエンドカムパニーインコーポレーテッド	置換アミド類
US7524885B2 (en) *	2002-04-01	2009-04-28	The Governors Of The University Of Alberta	Compounds that stimulate glucose utilization and methods of use
GB0212412D0 (en) *	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
ATE422884T1 (de) *	2002-06-03	2009-03-15	Novartis Pharma Gmbh	Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
ES2339112T3 (es) *	2002-08-21	2010-05-17	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG	8-(3-amino-piperidin-1-il)-xantinas,su preparacion y su uso como medicamentos.
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003264256A1 (en) *	2002-09-04	2004-03-29	Dsm Ip Assets B.V.	A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
MXPA05003252A (es) *	2002-09-26	2005-07-05	Eisai Co Ltd	Farmaco de combinacion.
ATE404191T1 (de) *	2002-12-10	2008-08-15	Novartis Pharma Ag	Kombinationen von einem dpp-iv inhibitor und einem ppar- alpha agonist
CA2518465A1 (fr)	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Inhibiteurs de dipeptidyle peptidase
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
EP1638554A1 (fr) *	2003-06-27	2006-03-29	Dr. Reddy's Research Foundation	Compositions comprenant de la balaglitazone et d'autres composes antidiabetiques
FR2858556B1 (fr) *	2003-08-06	2006-03-10	Galenix Innovations	Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP1663200A2 (fr) *	2003-09-02	2006-06-07	Prosidion Limited	Therapie combinee de regulation glycemique
EP1699777B1 (fr)	2003-09-08	2012-12-12	Takeda Pharmaceutical Company Limited	Inhibiteurs de la dipeptidylpeptidase
US20070149451A1 (en) *	2003-11-17	2007-06-28	Holmes David G	Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
WO2005049022A2 (fr)	2003-11-17	2005-06-02	Novartis Ag	Utilisation de composes organiques
RU2766487C2 (ru)	2004-01-20	2022-03-15	Новартис Аг	Композиция и способ прямого прессования
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
UA85871C2 (uk)	2004-03-15	2009-03-10	Такеда Фармасьютікал Компані Лімітед	Інгібітори дипептидилпептидази
JP2007261945A (ja) *	2004-04-07	2007-10-11	Taisho Pharmaceut Co Ltd	チアゾール誘導体
US7829720B2 (en)	2004-05-04	2010-11-09	Bristol-Myers Squibb Company	Process for preparing atazanavir bisulfate and novel forms
TWI415635B (zh) *	2004-05-28	2013-11-21	必治妥施貴寶公司	加衣錠片調製物及製備彼之方法
US7687638B2 (en)	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7935723B2 (en)	2004-06-04	2011-05-03	Novartis Pharma Ag	Use of organic compounds
WO2006019965A2 (fr)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Inhibiteurs de la dipeptidyl peptidase
US7842707B2 (en)	2004-07-23	2010-11-30	Nuada, Llc	Peptidase inhibitors
US20070259927A1 (en) *	2004-08-26	2007-11-08	Takeda Pharmaceutical Company Limited	Remedy for Diabetes
AU2005299808B2 (en) *	2004-10-25	2009-08-20	Novartis Ag	Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008524331A (ja)	2004-12-21	2008-07-10	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤
UA91698C2 (ru) *	2005-01-10	2010-08-25	Арена Фармасьютікалз, Інк.	Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшенных увеличением уровня glp-1 крови
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY145343A (en) *	2005-03-25	2012-01-31	Glaxo Group Ltd	Novel compounds
US20080096905A1 (en) *	2005-03-25	2008-04-24	Glaxo Group Limited	Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
KR20080000665A (ko)	2005-04-22	2008-01-02	알란토스 파마슈티컬즈 홀딩, 인코포레이티드	디펩티딜 펩티다아제-ⅳ 억제제
JP2008115080A (ja) *	2005-04-22	2008-05-22	Taisho Pharmaceutical Co Ltd	併用医薬
JP5586829B2 (ja) *	2005-06-03	2014-09-10	田辺三菱製薬株式会社	医薬の併用およびその用途
MY152185A (en) *	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
US20080207490A1 (en) *	2005-07-07	2008-08-28	Postech Foundation	Glucose Uptake Modulator and Method for Treating Diabetes or Diabetic Complications
CN101222919A (zh) *	2005-07-12	2008-07-16	诺瓦提斯公司	Dpp-ⅳ抑制剂与大麻素受体-1（cb1）拮抗物的组合
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
MY147393A (en)	2005-09-14	2012-11-30	Takeda Pharmaceutical	Administration of dipeptidyl peptidase inhibitors
CA2622642C (fr)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Inhibiteurs de dipeptidylpeptidase
EP1928499B1 (fr) *	2005-09-20	2011-06-29	Novartis AG	Utilisation d un inhibiteur de la ddp-iv en vue de réduire les crises d hypoglycémie
TW200738266A (en) *	2005-09-29	2007-10-16	Sankyo Co	Pharmaceutical agent containing insulin resistance improving agent
BRPI0616694B8 (pt) *	2005-09-29	2021-05-25	Novartis Ag	processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis
CA2623826A1 (fr) *	2005-09-30	2007-04-12	Novartis Ag	Combinaison de composes organiques
CN101365476A (zh) *	2005-10-07	2009-02-11	瓦拉塔药品公司	Dpp-iv抑制剂和胃泌素化合物的联合使用
CA2633167A1 (fr) *	2005-12-16	2007-07-12	Merck & Co., Inc.	Compositions pharmaceutiques contenant des combinaisons d'inhibiteurs de la dipeptidylpeptidase 4 avec de la metformine
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
JP5094416B2 (ja) *	2005-12-28	2012-12-12	武田薬品工業株式会社	糖尿病治療剤
FR2896157B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2007112347A1 (fr)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Inhibiteurs de la dipeptidyl peptidase
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US7833730B2 (en)	2006-04-11	2010-11-16	Arena Pharmaceuticals, Inc.	Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
EP2540725A1 (fr)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphes de 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
MX2009002772A (es) *	2006-09-13	2009-05-28	Takeda Pharmaceutical	Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro- 2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo.
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
JP2010043002A (ja) *	2006-11-27	2010-02-25	Ajinomoto Co Inc	糖尿病治療剤
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
TWI453041B (zh)	2007-02-01	2014-09-21	Takeda Pharmaceutical	固體型製劑
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (fr)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
PL2275108T3 (pl)	2008-05-14	2015-01-30	Sanwa Kagaku Kenkyusho Co	Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonej
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
CN102149407A (zh)	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
AR074797A1 (es) *	2008-10-10	2011-02-16	Japan Tobacco Inc	Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010062861A2 (fr)	2008-11-26	2010-06-03	Satiogen Pharmaceuticals, Inc.	Inhibiteurs de recyclage de l'acide biliaire pour le traitement de l'obésité et du diabète
CA2744697C (fr) *	2008-11-26	2016-06-21	Satiogen Pharmaceuticals, Inc.	Utilisation de compositions comprenant des acides biliaires, des sels et des semblables de ceux-ci pour le traitement de l'obesite ou du diabete
US8445538B2 (en) *	2008-12-19	2013-05-21	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds
CN102256976A (zh)	2008-12-23	2011-11-23	贝林格尔.英格海姆国际有限公司	有机化合物的盐形式
WO2010074271A1 (fr) *	2008-12-26	2010-07-01	武田薬品工業株式会社	Agent thérapeutique pour le diabète
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
JP5685550B2 (ja)	2009-02-13	2015-03-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EP2525790B1 (fr)	2009-10-21	2020-05-27	Agios Pharmaceuticals, Inc.	Procédés et compositions pour troubles associés à la prolifération cellulaire
WO2011050210A1 (fr)	2009-10-21	2011-04-28	Agios Pharmaceuticals, Inc.	Procedes et compositions pour des troubles relatifs
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011080276A1 (fr)	2009-12-29	2011-07-07	Genfit	Combinaisons pharmaceutiques comprenant un inhibiteur de dpp-4 et un dérivé de 1,3-diphénylprop-2-en-1-one
CA2795513A1 (fr)	2010-04-06	2011-10-13	Arena Pharmaceuticals, Inc.	Modulateurs du recepteur de gpr119 et traitement de troubles associes
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
ES2552657T3 (es)	2010-05-26	2015-12-01	Satiogen Pharmaceuticals, Inc.	Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
WO2011161161A1 (fr)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Thérapie du diabète
EP3323818A1 (fr)	2010-09-22	2018-05-23	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US20140018371A1 (en)	2011-04-01	2014-01-16	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (fr)	2011-04-19	2012-10-26	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
US20140051714A1 (en)	2011-04-22	2014-02-20	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en)	2011-04-22	2014-02-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (fr)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
US8883800B2 (en)	2011-07-15	2014-11-11	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013055910A1 (fr)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés
AU2012328526B2 (en)	2011-10-28	2017-05-25	Shire Human Genetic Therapies, Inc.	Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20130108573A1 (en)	2011-10-28	2013-05-02	Lumena Pharmaceuticals, Inc.	Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
EA021236B1 (ru) *	2012-10-03	2015-05-29	Дафот Энтерпраизес Лимитед	Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
WO2014074668A1 (fr)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
EP3110449B1 (fr)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Utilisation médicale d'un inhibiteur de dpp-4
EA201791982A1 (ru)	2015-03-09	2020-02-17	Интекрин Терапьютикс, Инк.	Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
WO2018162722A1 (fr)	2017-03-09	2018-09-13	Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke	Inhibiteurs de dpp-4 à utiliser dans le traitement de fractures osseuses
JP2020515639A (ja)	2017-04-03	2020-05-28	コヒラス・バイオサイエンシズ・インコーポレイテッド	進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
JP2022548214A (ja)	2019-09-17	2022-11-17	ノバルティスアーゲー	ビルダグリプチンとメトホルミンとの組み合わせ療法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US489795A (en)		1893-01-10		Steadying device for portable engines
US988496A (en)	1910-09-19	1911-04-04	Henry Obermann	Ventilator.
US4062950A (en) *	1973-09-22	1977-12-13	Bayer Aktiengesellschaft	Amino sugar derivatives
JPS5522636A (en)	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
US4342771A (en) *	1981-01-02	1982-08-03	Pfizer Inc.	Hypoglycemic 5-substituted oxazolidine-2,4-diones
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
DE3347565A1 (de)	1983-12-30	1985-07-11	Thomae Gmbh Dr K	Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5216167A (en) *	1983-12-30	1993-06-01	Dr. Karl Thomae Gmbh	Phenylacetic acid benzylamides
AR240698A1 (es)	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
JPS6354321A (ja)	1985-03-27	1988-03-08	Ajinomoto Co Inc	血糖降下剤
HU210339B (en)	1985-05-21	1995-03-28	Pfizer	Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5071773A (en)	1986-10-24	1991-12-10	The Salk Institute For Biological Studies	Hormone receptor-related bioassays
EP0842925A1 (fr)	1987-09-04	1998-05-20	Beecham Group Plc	Thiazolidinédiones substituées
US4981784A (en)	1987-12-02	1991-01-01	The Salk Institute For Biological Studies	Retinoic acid receptor method
MX15171A (es)	1988-03-08	1993-05-01	Pfizer	Derivados de tiazolidinodiona hipoglicemicos
EP0497894A4 (en)	1989-10-25	1993-03-31	The Salk Institute For Biological Studies	Receptor infection assay
US4997948A (en)	1989-10-27	1991-03-05	American Home Products	5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
AU637446B2 (en)	1990-01-16	1993-05-27	Baylor College Of Medicine	Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
DK0552202T3 (da)	1990-09-21	1996-06-03	Salk Inst For Biological Studi	Fremgangsmåder medieret af det protoonkogene proteinkompleks AP-1
ES2100291T3 (es)	1991-07-30	1997-06-16	Ajinomoto Kk	Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos.
US5866563A (en)	1991-09-30	1999-02-02	The University Of British Columbia	Vanadium compositions
WO1993011235A1 (fr)	1991-12-06	1993-06-10	The Salk Institute For Biological Studies	Formes multimeres des membres de la superfamille des recepteurs steroides/thyroides
JP4001618B2 (ja)	1991-12-18	2007-10-31	ザソールクインスチチュートフォアバイオロジカルスタディズ	レチノイド受容体によって仲介される過程の修飾方法およびそれに有用な化合物
ATE195716T1 (de)	1992-04-22	2000-09-15	Ligand Pharm Inc	Retinoid-x rezeptor selektive verbindungen
EP0745121B1 (fr)	1992-05-14	2007-06-20	Baylor College Of Medicine	Recepteurs d'hormones steroides mutees, procede d'utilisation et commutateur moleculaire pour therapie genique
US5466861A (en)	1992-11-25	1995-11-14	Sri International	Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
JP2845743B2 (ja)	1992-12-28	1999-01-13	三菱化学株式会社	新規なナフタレン誘導体
ES2129115T3 (es)	1993-01-11	1999-06-01	Ligand Pharm Inc	Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x.
JPH08505852A (ja)	1993-01-11	1996-06-25	リガンド・ファーマシューティカルズ・インコーポレーテッド	レチノイドｘレセプターに対する選択性を有する化合物
WO1994015901A1 (fr)	1993-01-11	1994-07-21	Ligand Pharmaceuticals Inc.	Composes activant selectivement les recepteurs de retinoides x
US5399586A (en)	1993-03-11	1995-03-21	Allergan, Inc.	Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
JPH08512197A (ja)	1993-04-07	1996-12-24	リガンド・ファーマシューティカルズ・インコーポレーテッド	受容体アゴニストのスクリーニング方法
US5506102A (en)	1993-10-28	1996-04-09	Ligand Pharmaceuticals Incorporated	Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
EP0737314A4 (fr)	1993-12-30	1999-11-03	Salk Inst For Biological Studi	Nouvelles utilisations de produits de recombinaison de recepteurs de gal4
US5705515A (en)	1994-04-26	1998-01-06	Merck & Co., Inc.	Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
DE4416433A1 (de)	1994-05-10	1995-11-16	Hoechst Ag	Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten
US5488510A (en)	1994-07-26	1996-01-30	Lemay; Edward J.	Enhanced depth perception viewing device for television
PL180048B1 (en)	1994-08-10	2000-12-29	Fhoffmann La Roche Ag	Ligands of retinic acid x-receptors
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
CN1121374C (zh)	1994-12-30	2003-09-17	配位体药物股份有限公司	新的三烯类视黄酸化合物及方法
AU714710B2 (en)	1994-12-30	2000-01-06	Ligand Pharmaceuticals Incorporated	Tricyclic retinoids, methods for their production and use
FI974437A7 (fi)	1995-06-06	1997-12-05	Pfizer	Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
DE69523182T2 (de)	1995-06-06	2002-02-07	Pfizer	Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
AU702887B2 (en)	1995-10-31	1999-03-11	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AU2090897A (en)	1996-02-29	1997-09-16	Mikael Bols	Hydroxyhexahydropyridazines
US5770615A (en)	1996-04-04	1998-06-23	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
DE122010000020I1 (de) *	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
WO1997041854A1 (fr)	1996-05-07	1997-11-13	The Trustees Of The University Of Pennsylvania	Inhibiteurs de glycogene synthetase kinase-3 et procedes d'identification et d'utilisation de ces inhibiteurs
WO1997046556A1 (fr)	1996-06-07	1997-12-11	Merck & Co., Inc.	BENZENESULFONAMIDES D'OXADIAZOLE EN TANT QU'AGONISTES β3 SELECTIFS POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
ES2171839T3 (es)	1996-09-05	2002-09-16	Lilly Co Eli	Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
JP4010377B2 (ja)	1996-09-06	2007-11-21	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US5776954A (en)	1996-10-30	1998-07-07	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
FR2755439B1 (fr)	1996-11-05	1998-12-24	Virbac Sa	Derives aryloxypropanolamines, leur procede de preparation et leurs applications
TW492957B (en) *	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO1998021957A1 (fr)	1996-11-20	1998-05-28	Merck & Co., Inc.	Imidazoles a substitution triaryle, compositions renfermant de tels composes et modes d'utilisation
US5880139A (en)	1996-11-20	1999-03-09	Merck & Co., Inc.	Triaryl substituted imidazoles as glucagon antagonists
EP0959886A4 (fr)	1996-11-20	2001-05-02	Merck & Co Inc	Imidazoles a substitution triaryle en tant qu'antagonistes du glucagon
EP0959885A4 (fr)	1996-11-20	2002-07-17	Merck & Co Inc	Imidazoles a substitution triaryle et leurs procedes d'utilisation
US5952322A (en)	1996-12-05	1999-09-14	Pfizer Inc.	Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
ID22273A (id)	1997-01-28	1999-09-23	Merck & Co Inc	TIAZOL BENZENASULFONAMIDA SEBAGAI AGONIS β UNTUK PENGOBATAN DIABETES DAN OBESITAS
US6284748B1 (en)	1997-03-07	2001-09-04	Metabasis Therapeutics, Inc.	Purine inhibitors of fructose 1,6-bisphosphatase
DE69819311T2 (de)	1997-03-07	2004-07-29	Metabasis Therapeutics Inc., San Diego	Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
EP0973778A1 (fr)	1997-03-07	2000-01-26	Novo Nordisk A/S	DERIVES DE 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE, LEUR PREPARATION ET LEUR UTILISATION
US6054587A (en)	1997-03-07	2000-04-25	Metabasis Therapeutics, Inc.	Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
BR9810378A (pt)	1997-07-01	2000-08-29	Novo Nordisk As	Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
GB9715298D0 (en) *	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
AU9253798A (en)	1997-09-23	1999-04-12	Novo Nordisk A/S	Modules of protein tyrosine phosphatases (ptpases)
UA57811C2 (uk)	1997-11-21	2003-07-15	Пфайзер Продактс Інк.	Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
WO1999029672A1 (fr)	1997-12-05	1999-06-17	Eli Lilly And Company	AGONISTES β3-ADRENERGIQUES SPECIFIQUES
EP2583675A1 (fr) *	1998-02-02	2013-04-24	Trustees Of Tufts College	Utilisation d'inhibiteurs de la dipeptidylpeptidase pour réguler le métabolisme du glucose
WO1999040062A1 (fr)	1998-02-05	1999-08-12	Novo Nordisk A/S	Derives d'hydrazone
US5998463A (en)	1998-02-27	1999-12-07	Pfizer Inc	Glycogen phosphorylase inhibitors
WO1999046236A1 (fr)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulateurs de proteine tyrosine phosphatases (ptpases)
WO1999046244A1 (fr)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulateurs de proteine tyrosine phosphatases (ptpases)
WO1999046267A1 (fr)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulateurs de proteine tyrosine phosphatases (ptpases)
WO1999046237A1 (fr)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulateurs de proteine-tyrosine-phosphatases
EP1062218A1 (fr)	1998-03-12	2000-12-27	Novo Nordisk A/S	MODULATEURS DE PROTEINE TYROSINE PHOSPHATASES (PTPases)
WO1999047549A1 (fr)	1998-03-16	1999-09-23	Ontogen Corporation	Piperazines utilisees en tant qu'inhibiteurs de fructose-1,6-bisphosphatase (fbpase)
EP1073643B1 (fr)	1998-04-23	2004-12-29	Dr. Reddy's Laboratories Ltd.	Nouveaux composes heterocycliques, leur utilisation en medecine, leur procede de preparation et compositions pharmaceutiques les contenant
US6331633B1 (en)	1998-05-08	2001-12-18	Calyx Therapeutics Inc.	Heterocyclic analogs of diphenylethylene compounds
US6001867A (en)	1998-05-12	1999-12-14	American Home Products Corporation	1-aryl-dibenzothiophenes
EP1077967B1 (fr)	1998-05-12	2002-12-04	Wyeth	Acides biphenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
US6057316A (en)	1998-05-12	2000-05-02	American Home Products Corporation	4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
AU3791699A (en)	1998-05-12	1999-11-29	American Home Products Corporation	Naphtho{2,3-b}heteroar-4-yl derivatives
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
EP0978279A1 (fr)	1998-08-07	2000-02-09	Pfizer Products Inc.	Inhibiteurs de la glycogene phosphorylase
WO2000014090A1 (fr)	1998-09-02	2000-03-16	Novo Nordisk A/S	Derives de 4,5,6,7-tetrahydro-thieno[2,3-c]pyridine
KR100818845B1 (ko)	1998-09-09	2008-04-01	메타베이시스 테라퓨틱스, 인크.	신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
AU6111699A (en)	1998-10-08	2000-05-01	Smithkline Beecham Plc	Novel method and compounds
CO5150173A1 (es) *	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB2351081A (en)	1999-06-18	2000-12-20	Lilly Forschung Gmbh	Pharmaceutically active imidazoline compounds and analogues thereof
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US6030837A (en)	1999-08-03	2000-02-29	Isis Pharmaceuticals Inc.	Antisense inhibition of PEPCK-mitochondrial expression
EP1743655B1 (fr) *	2000-01-21	2014-06-25	Novartis AG	Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
TW200303742A (en) †	2001-11-21	2003-09-16	Novartis Ag	Organic compounds

2001
- 2001-01-19 EP EP06121898.8A patent/EP1743655B1/fr not_active Expired - Lifetime
- 2001-01-19 ES ES06121898.8T patent/ES2487897T3/es not_active Expired - Lifetime
- 2001-01-19 AT AT06121895T patent/ATE385421T1/de active
- 2001-01-19 CN CNA2006101699199A patent/CN1977842A/zh active Pending
- 2001-01-19 CN CN01803953A patent/CN1400908A/zh active Pending
- 2001-01-19 WO PCT/EP2001/000590 patent/WO2001052825A2/fr not_active Ceased
- 2001-01-19 ES ES06121896.2T patent/ES2436610T3/es not_active Expired - Lifetime
- 2001-01-19 DE DE122008000018C patent/DE122008000018I1/de active Pending
- 2001-01-19 DK DK06121895T patent/DK1741446T3/da active
- 2001-01-19 DE DE60124861T patent/DE60124861T2/de not_active Expired - Lifetime
- 2001-01-19 CA CA2673615A patent/CA2673615C/fr not_active Expired - Lifetime
- 2001-01-19 EP EP01909661A patent/EP1248604B2/fr not_active Expired - Lifetime
- 2001-01-19 AU AU2001237321A patent/AU2001237321A1/en not_active Abandoned
- 2001-01-19 JP JP2001552873A patent/JP2003520226A/ja active Pending
- 2001-01-19 EP EP06121894.7A patent/EP1741445B1/fr not_active Expired - Lifetime
- 2001-01-19 DK DK06121898.8T patent/DK1743655T3/da active
- 2001-01-19 DK DK06121896.2T patent/DK1741447T3/da active
- 2001-01-19 PT PT61218988T patent/PT1743655E/pt unknown
- 2001-01-19 EP EP06121896.2A patent/EP1741447B1/fr not_active Expired - Lifetime
- 2001-01-19 PT PT06121895T patent/PT1741446E/pt unknown
- 2001-01-19 ES ES06121894T patent/ES2433476T3/es not_active Expired - Lifetime
- 2001-01-19 ES ES06121895T patent/ES2301142T3/es not_active Expired - Lifetime
- 2001-01-19 DK DK01909661.9T patent/DK1248604T4/da active
- 2001-01-19 PT PT61218947T patent/PT1741445E/pt unknown
- 2001-01-19 DK DK06121894.7T patent/DK1741445T3/da active
- 2001-01-19 PT PT01909661T patent/PT1248604E/pt unknown
- 2001-01-19 DE DE60132723T patent/DE60132723T2/de not_active Expired - Lifetime
- 2001-01-19 BR BRPI0107715A patent/BRPI0107715B8/pt not_active IP Right Cessation
- 2001-01-19 EP EP06121895A patent/EP1741446B1/fr not_active Expired - Lifetime
- 2001-01-19 AT AT01909661T patent/ATE346613T1/de active
- 2001-01-19 CN CN2011102233943A patent/CN102327614A/zh active Pending
- 2001-01-19 US US10/181,169 patent/US20030139434A1/en not_active Abandoned
- 2001-01-19 CA CA002397554A patent/CA2397554C/fr not_active Expired - Lifetime
- 2001-01-19 PT PT61218962T patent/PT1741447E/pt unknown
- 2001-01-19 ES ES01909661T patent/ES2275654T5/es not_active Expired - Lifetime
2006
- 2006-07-10 JP JP2006189416A patent/JP2006273873A/ja active Pending
- 2006-12-29 CY CY20061101859T patent/CY1106303T1/el unknown
2008
- 2008-04-24 CY CY20081100459T patent/CY1107423T1/el unknown
- 2008-05-09 LU LU91436C patent/LU91436I2/fr unknown
- 2008-05-12 CY CY200800010C patent/CY2008010I1/el unknown
- 2008-05-14 FR FR08C0017C patent/FR08C0017I2/fr active Active
- 2008-05-14 NL NL300346C patent/NL300346I1/nl unknown
2011
- 2011-03-02 JP JP2011045331A patent/JP5835910B2/ja not_active Expired - Lifetime
- 2011-03-30 JP JP2011076253A patent/JP5824224B2/ja not_active Expired - Lifetime
2013
- 2013-10-09 CY CY20131100877T patent/CY1114466T1/el unknown
- 2013-11-08 CY CY20131100996T patent/CY1114593T1/el unknown
2014
- 2014-02-06 JP JP2014020963A patent/JP6095589B2/ja not_active Expired - Lifetime
- 2014-08-08 CY CY20141100633T patent/CY1115449T1/el unknown
2015
- 2015-07-31 JP JP2015151372A patent/JP6104331B2/ja not_active Expired - Lifetime
2017
- 2017-01-19 JP JP2017007638A patent/JP6374995B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
HK1102424A1 (en)	2007-11-23
JP6374995B2 (ja)	2018-08-15
EP1743655B1 (fr)	2014-06-25
CA2673615C (fr)	2013-07-16
CA2397554C (fr)	2009-09-22
PT1743655E (pt)	2014-09-09
EP1741447A2 (fr)	2007-01-10
EP1741446B1 (fr)	2008-02-06
CA2397554A1 (fr)	2001-07-26
PT1741446E (pt)	2008-05-09
ES2436610T3 (es)	2014-01-03
DK1741447T3 (da)	2013-12-09
CY1115449T1 (el)	2017-01-04
PT1741445E (pt)	2013-11-11
PT1248604E (pt)	2007-01-31
FR08C0017I1 (fr)	2008-07-18
EP1741446A2 (fr)	2007-01-10
JP5824224B2 (ja)	2015-11-25
DE60132723T2 (de)	2009-01-29
DK1741446T3 (da)	2008-06-02
ES2275654T5 (es)	2012-06-07
HK1102422A1 (en)	2007-11-23
DE60124861T2 (de)	2007-05-10
EP1741447B1 (fr)	2013-09-18
ATE385421T1 (de)	2008-02-15
CN102327614A (zh)	2012-01-25
JP2017081994A (ja)	2017-05-18
JP5835910B2 (ja)	2015-12-24
ATE346613T1 (de)	2006-12-15
PT1741447E (pt)	2013-12-11
ES2301142T3 (es)	2008-06-16
FR08C0017I2 (fr)	2010-12-31
CN1977842A (zh)	2007-06-13
HK1108359A1 (en)	2008-05-09
BRPI0107715B1 (pt)	2016-07-05
JP2015214572A (ja)	2015-12-03
AU2001237321A1 (en)	2001-07-31
EP1741445A3 (fr)	2007-01-24
ES2433476T3 (es)	2013-12-11
ES2487897T3 (es)	2014-08-25
HK1102405A1 (en)	2007-11-23
JP6095589B2 (ja)	2017-03-15
EP1741445B1 (fr)	2013-08-14
WO2001052825A2 (fr)	2001-07-26
CN1400908A (zh)	2003-03-05
CY1106303T1 (el)	2011-10-12
DK1248604T3 (da)	2007-02-19
EP1741445A2 (fr)	2007-01-10
JP2011116772A (ja)	2011-06-16
NL300346I1 (fr)	2008-07-01
DK1741445T3 (da)	2013-11-04
DE60124861D1 (de)	2007-01-11
DK1248604T4 (da)	2012-05-21
EP1741447A3 (fr)	2007-01-17
EP1248604B1 (fr)	2006-11-29
ES2275654T3 (es)	2007-06-16
EP1248604B2 (fr)	2012-02-29
US20030139434A1 (en)	2003-07-24
LU91436I9 (fr)	2019-01-02
EP1248604A2 (fr)	2002-10-16
EP1743655A1 (fr)	2007-01-17
DE60132723D1 (de)	2008-03-20
BR0107715A (pt)	2002-11-19
JP2003520226A (ja)	2003-07-02
CY2008010I2 (el)	2009-11-04
CY1107423T1 (el)	2010-07-28
JP2011162550A (ja)	2011-08-25
EP1741446A3 (fr)	2007-01-17
JP2014088435A (ja)	2014-05-15
BRPI0107715B8 (pt)	2021-05-25
DK1743655T3 (da)	2014-08-18
CY1114593T1 (el)	2016-10-05
JP6104331B2 (ja)	2017-03-29
CY2008010I1 (el)	2009-11-04
CA2673615A1 (fr)	2001-07-26
DE122008000018I1 (de)	2008-08-14
JP2006273873A (ja)	2006-10-12
WO2001052825A3 (fr)	2002-03-28
CY1114466T1 (el)	2016-10-05

Publication	Publication Date	Title
LU91436I2 (fr)	2008-07-09	"Combinaison comprenant de la vildagliptine ou un de ses sels pharmaceutiquement acceptable et de lametformine ou un de ses sels pharmaceutiquement a cceptable (EUCREAS)"
WO2004048345A3 (fr)	2004-07-15	Composes destines au traitement de l'obesite
WO2002038544A3 (fr)	2002-09-26	Agonistes du recepteur beta-3 d'oxindole 3-substitue
WO2006070195A8 (fr)	2006-08-24	Composes de pyrazole regulant l’activite de kinases cdk, gsk et aurora
CA2432799A1 (fr)	2002-06-27	Composes de pyrazole presentant une grande utilite comme inhibiteurs de proteine kinase
BR0212477A (pt)	2004-08-24	7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
CA2368059A1 (fr)	2000-09-21	Heterocycles bicycliques, compositions pharmaceutiques contenant ces composes, utilisations et procedes de preparation de ces derniers
BRPI0518409A2 (pt)	2008-11-18	combinaÇço de inibidor dpp-iv, antidiabÉtico ppar e metformina
CN101765593A (zh)	2010-06-30	用作大麻素受体配体的2-亚氨基异噻唑衍生物
Doods et al.	1993	Characterization of muscarinic receptors in guinea-pig uterus
GR3034904T3 (en)	2001-02-28	Endothelin antagonists.
NO20065489L (no)	2006-11-28	Tieno[3,2-b]pyridin-6-karbonitriler som protein-kinase inhibitorer
WO2006084757A3 (fr)	2006-11-23	Combinaison de sel ca/mg de valsartan avec un agent antidiabetique
WO2000076457A3 (fr)	2001-05-17	Antagonistes du recepteur il-8
WO2006100026A8 (fr)	2007-02-08	2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepine-3-yl-piperidines constituant des antagonistes de cgrp
WO2002061083A1 (fr)	2002-08-08	Nouvelle proteine de recepteur couple aux proteines g et son adn
WO2002004624A9 (fr)	2002-03-28	Nouvelle proteine receptrice couplee a la proteine g et adn destine a celle-ci
HK1044475A1 (zh)	2002-10-25	Il-8受体拮抗剂